Holen Sie sich die Stockscreener-App
634.42
0.81%
-4.46
Handel nachbörslich:
636.34
1.92
+0.30%
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing - The Motley Fool
U.S. biotech giant Regeneron chooses Hyderabad to set up GCC - The Hindu
Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event - Insider Monkey
Important Notice to Long-Term Shareholders of Molina - GlobeNewswire
US biotech giant Regeneron to set up its first Global Capability Centre outside America in Hyderabad - NewsMeter
Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink? - Yahoo Finance
Regeneron Pharmaceuticals to set up Global Capability Centre (GCC) in Hyderabad - Telangana Today
Legal & General Group Plc Sells 27,332 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
US biotech major Regeneron identifies site for its GCC to be operational in 2nd half of 2026 in Hyderabad - Pharmabiz.com
Prospera Financial Services Inc Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Jefferies Financial Group Inc. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
US Biotech Regeneron to launch Global Capability Centre in Hyderabad - BioSpectrum India
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Trial Wins And New Research Partnership - simplywall.st
US biotech Regeneron to launch global capability centre in India's Hyderabadstatement - marketscreener.com
Regeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target ‘Undruggable’ Proteins - Yahoo! Finance Canada
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) - marketscreener.com
5 Cheap NASDAQ Stocks to Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Simplify Asset Management Inc. - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN): Analyst Ratings Signal Strong Buy with 30% Upside Potential - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire about Securities Investigation - ACCESS Newswire
The week in pharma: action, reaction and insight – week to May 22, 2026 - The Pharma Letter
Why Regeneron (REGN) Is Down 8.5% After Melanoma Trial Miss and New Legal ScrutinyAnd What's Next - simplywall.st
Swedbank AB Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by LSV Asset Management - MarketBeat
Regeneron R&D Updates Test Market View On Long Term Pipeline Value - Yahoo Finance
Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron - Yahoo Finance
ABN Amro Investment Solutions Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Lynozyfic AL Amyloidosis Data Gives Regeneron Pipeline And Valuation Focus - simplywall.st
Regeneron (REGN) Advances Gene Therapy Review in Europe - GuruFocus
Licensable picture: The exterior of Regeneron Pharmaceuticals May 22, 2026 in Tarrytown. - Reuters Connect
Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials (PBLS) - Seeking Alpha
Regeneron Says Otarmeni Application Accepted Under EU Accelerated Assessment - Moomoo
EMA accepts Regeneron’s gene therapy for rare hearing loss By Investing.com - Investing.com Canada
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss - The Manila Times
Rx Rundown: Parabilis Medicines, Boston Scientific, Amgen and more - Medical Marketing and Media
REGN News | REGENERON PHARMACEUTICALS (NASDAQ:REGN) - ChartMill
(REGN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Regeneron reports positive trial results for amyloidosis treatment By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals Reports Encouraging LINKER-AL2 Trial Results for Lynozyfic® in Systemic AL Amyloidosis - Quiver Quantitative
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals, Inc. Cash Flow – BVL:REGNUS - TradingView
Jim Cramer on Regeneron: “There Could Be Some More Downgrades” - Insider Monkey
Levi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN) - GlobeNewswire
Regeneron-backed Parabilis Medicines seeks US IPO - MSN
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron backed Parabilis Medicines seeks U.S. IPO - Seeking Alpha
Why Regeneron (REGN) Shares Are Trading Lower Today - Yahoo Finance
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Business Wire
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets - Yahoo Finance
Tredje AP fonden Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Resona Asset Management Co. Ltd. Has $24.71 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ProShare Advisors LLC Has $142.25 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Harvest Portfolios Group Inc. Has $63.10 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Scotiabank Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $770 - Moomoo
Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy - Moomoo
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B - Yahoo Finance
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance Singapore
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback - Yahoo Finance
Regeneron Stock Tumbles 12% After Experimental Cancer Drug Misses Key Trial Goal - TIKR.com
REGN Maintained by Canaccord Genuity -- Price Target Lowered to $875 - GuruFocus
Canaccord Genuity Group Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $875.00 - MarketBeat
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $770 to $968 - Moomoo
Company News for May 19, 2026 - Yahoo Finance
REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations – Company AnnouncementFT.com - Financial Times
0.16%
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):